Disarm Therapeutics Unveils Breakthrough Approach to Treat Neurological Diseases

Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, today announced the recent completion of a $30 million Series A financing. The round was led by Atlas Venture, with co-investors Lightstone Ventures and AbbVie Ventures.  Disarm was co-founded, seeded, and incubated in 2016 by Atlas Venture, together with Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis.

Axonal degeneration causes disability and disease progression in a broad range of chronic and acute diseases of the central, ocular, and peripheral nervous systems. Disarm is developing therapeutics to inhibit the SARM1 protein, recently identified by Disarm’s scientific founders as the central driver of axonal degeneration. Based on this discovery, Disarm is pioneering a breakthrough treatment approach for patients with neurological diseases.

Read Full Article